ALS drug from Denali, Sanofi falls short in mid-stage study
Denali Therapeutics and Sanofi's ALS drug failed Phase 2 trial, missing the primary endpoint on the ALSFRS-R scale. Despite the setback, Sanofi continues testing the drug for multiple sclerosis. Denali is also developing another ALS drug, DNL343, targeting nerve cell death mechanisms.
Reference News
Denali Therapeutics and Sanofi's ALS drug failed Phase 2 trial, missing the primary endpoint on the ALSFRS-R scale. Despite the setback, Sanofi continues testing the drug for multiple sclerosis. Denali is also developing another ALS drug, DNL343, targeting nerve cell death mechanisms.
Sanofi and Denali Therapeutics' ALS therapy, SAR443820/DNL788, failed its Phase II HIMALAYA study primary endpoint. Despite this, it's still in development for multiple sclerosis. The therapy targets RIPK1 protein to combat neuroinflammation. The partnership has faced clinical setbacks, including the suspension of DNL747 and discontinuation of DNL758 in certain conditions.
Denali Therapeutics and Sanofi's ALS drug failed to slow motor function decline in a mid-stage study, marking another setback in ALS treatment development. The drug did not meet the main goal on the ALS functional rating scale. Sanofi will continue testing the drug for multiple sclerosis. ALS affects nerve cells, leading to paralysis and death.
Denali Therapeutics announced that its drug for a neurological disease, developed with Sanofi, failed to meet the primary endpoint in a mid-stage trial.
Denali Therapeutics' shares dropped 7.4% to $17.01 after its Phase 2 Himalaya study for ALS treatment with SAR443820/DNL788 missed the primary endpoint. The stock has fallen 22% YTD and 45% over the past year. Sanofi will proceed with a Phase 2 study for multiple sclerosis.